Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



AbbVie Announces Positive Updates on its Clinical Program for ABBV-RGX-314

January 14, 2025
AbbVie Inc. (NYSE: ABBV), a global pharmaceutical company, has recently announced positive updates on its clinical program for ABBV-RGX-314, in collaboration with REGENXBIO. This program aims to develop a gene therapy for the treatment of retinal diseases. The updates reveal promising results from ongoing clinical trials, demonstrating the potential of ABBV-RGX-314 to address the unmet needs of patients suffering from retinal diseases. The news has positively impacted AbbVie's stock, which saw a 0.32% increase in its value. Investors and analysts are closely monitoring the progress of ABBV-RGX-314 as it has the potential to significantly contribute to AbbVie's future growth. Considering the positive updates and the company's strong position in the pharmaceutical industry, professionals from Stocks Prognosis recommend considering an investment in AbbVie stocks for potential long-term gains.
If you want to leave a comment, then you need Login or Register





Other data for ABBV

Related data

ABBVSeptember 2, 2025ABBVIE INC. Hits Price Target Forecast Profit of 11.94% on QuantWave  ~1 min.

On July 30, 2025, QuantWave, the automated forecasting platform, issued a long signal for ABBVIE INC. stock when it was trading at 189.31 $....


ABBVAugust 20, 2025ABBVIE INC. Hits Forecast Price Target with 10.4% Profit: A Success Story for QuantWave  ~1 min.

On June 13, 2025, QuantWave issued a long signal for ABBVIE INC. when the stock was trading at 189.44 $. Fast forward to August 20, 2025, and the forecasted price target of 209....


ABBVAugust 14, 2025ABBVIE INC. Hits Price Target Forecast with 11.3% Profit: QuantWave Analysis  ~1 min.

ABBVIE INC. has successfully reached the price target forecast set by QuantWave, resulting in an impressive 11.3% profit for investors....


ABBVMarch 22, 2025AbbVie ABBV Stock Moves -0.29: What You Should Know  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, has recently experienced a slight decrease in stock movement. As an investor, it is essential to keep track of such fluctuations....


ABBVMarch 20, 2025AbbVie Inc. ABBV is Experiencing Global Investor Interest: A Look into the Company's Success Story  ~2 min.

AbbVie Inc., a renowned pharmaceutical company, has been making waves in the global market, attracting significant attention from investors worldwide....


ABBVMarch 19, 2025AbbVie Inc. ABBV: A Higher-Yielding Healthcare Play That Continues to Shine  ~1 min.

AbbVie Inc., a renowned pharmaceutical company, is steadily gaining the attention of investors. With its continuous success in the healthcare industry, AbbVie has become a top choice for hedge funds....


ABBVMarch 18, 2025The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell, and Hamilton Beach Brands  ~1 min.

According to a recent analysis by Zacks, AbbVie Inc. (ABBV) is considered one of the top healthcare stocks to invest in....


ABBVMarch 14, 2025AbbVie Inc. ABBV is Attracting Investor Attention: Here is What You Should Know  ~2 min.

AbbVie Inc. (ABBV) has been grabbing the attention of investors recently with its impressive performance in the healthcare sector....


ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast with 15.28% Profit – A Triumph for QuantWave's Analytics  ~1 min.

ABBVIE INC. achieved a significant milestone as it hit the price target forecast set by QuantWave, resulting in a profit of 15.28%....


ABBVMarch 10, 2025ABBVIE INC. Hits Price Target Forecast on QuantWave with 15.28% Profit Margin  ~1 min.

AbbVie Inc. (ABBV) has successfully reached the price target forecast on QuantWave, signaling a profitable long position for investors. The forecast, initiated on August 13, 2024, at a price of $184....


GSKNovember 28, 2024GSK submits multiple myeloma treatment for approval to the US regulator  ~1 min.

GSK, a leading pharmaceutical company, has recently submitted its groundbreaking treatment for multiple myeloma to the US regulator for approval....


VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, driving growth and attracting investors....


PFENovember 21, 2024Pfizer Inc. Introduces Groundbreaking Immunotherapy Treatment, Boosting Confidence in PFE Stock  ~2 min.

Pfizer Inc., a leading pharmaceutical company, has announced the development of a groundbreaking immunotherapy treatment that could revolutionize cancer treatment....


VRTXMarch 19, 2025Investing in Vertex Pharmaceuticals: A Lucrative Opportunity for Biotech Enthusiasts  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has emerged as one of the most promising biotech stocks in the market, attracting the attention of top investors....